A dose-escalation committee was responsible for the review of safety data at specified time points, to assess whether an escalation or reduction in dose should be administered in the subsequent cohort and to determine when the maximum-tolerated dose had been attained.
evidence of successful engraftment as demonstrated by an absolute neutrophil count ≥500/mm 3 and platelets ≥20,000/mm 3 without transfusions; no Grade ≥2 acute graft-versus-host disease; subject was in CRc.
Assessments

Safety and Tolerability
Physical examinations and blood samples for clinical laboratory assessments were collected on Day -2; Day - additional ECG tests were conducted on Day -2 and on Cycle 1 Day 15 at 2 h, 4 h, 6 h, and 24 h post dose.
However, if a >30 ms increase in QTcF was observed from Day 1 to Day 8, an additional ECG evaluation was performed on Cycle 1 Day 9. Recordings were performed in triplicate at each time point and transmitted electronically for central reading.
Pharmacokinetic and Pharmacodynamic Assessments
For single-dose evaluation, gilteritinib was orally administered on Day -2 and blood samples were drawn on Day -2 prior to dose (0 h) and at 30 min, 1 h, 2 h, 4 h, 6 h, 24 h, and 48 h post dose. Once-daily administration of gilteritinib began following a 48 h observation period after the initial dose (Cycle 1 Day 1). Multiple-dose PK was investigated on Day 15; blood samples were drawn on Cycle 1 Day 15 prior to dose (0 h) and at 30 min, 1 h, 4 h, 6
h, and 24 h post dose. Plasma samples were analyzed for gilteritinib concentrations using a validated liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method.
The percentage inhibition of phosphorylation of FLT3, AXL, and S6 was assessed in whole-blood samples (4 mL) that were collected during the dose-escalation and -expansion phases. For the dose-escalation phase, blood samples for the plasma inhibitory activity assay of FLT3 were collected on Days −1 and −2; Cycle 1 Days 1, 8±1, 15, and 16; and Cycle 2 Day 1±3. Blood samples at Day −2 and Cycle 1 Day 15 were collected pre-dose (0.5 h before drug administration) and post-dose at 2±10 minutes, 6±20 minutes, and 24 h±90 minutes (the 24-h sample was collected on Day −1 and before the next dose of gilteritinib on Day 16). For the dose-expansion phase, blood samples for PIA were obtained pre-dose (0.5 h before drug administration) and post-dose (2 h after drug administration) on Days 1, 8±1, 15±1 of Cycle 1 and on Day 1±3 of Cycle 2. Tables   Table S1 . Definitions for antileukemic responses
Clinical response term Definition
Complete remission Patients must have bone marrow regenerating normal hematopoietic cells and achieve a morphologic leukemia-free state. They must have an absolute neutrophil count >1 × 10 9 /L, a platelet count ≥100 × 10 9 /L, and normal marrow differential with <5% blasts. Patients will be independent of red blood cell and platelet transfusion (defined as 1 week without red blood cell transfusion and 1 week without platelet transfusion). There should be no evidence of extramedullary leukemia.
Complete remission with incomplete platelet recovery (CRp)
Response meets all of the criteria for CR except that the platelet count is <100 × 10 9 /L (Sievers EL, Larson RA, Stadtmauer EA, et al. J Clin Oncol 2001; 19:3244-54) .
Complete remission with incomplete hematological recovery (CRi)
Response meets all of the criteria for CR except subject experiences residual neutropenia (<1 × 10 9 /L) with or without complete platelet recovery. Transfusion independence is not required.
Partial remission
Evidence of peripheral recovery with no (or only a few regenerating) circulating blasts and a reduction in marrow blasts to 5-25%, with a reduction of ≥50% from baseline pretreatment level.
Relapse
Relapse after CR, CRp, or CRi is defined as the reappearance of leukemic blasts in the peripheral blood or ≥5% of blasts in the bone marrow aspirate not attributable to any other cause, or reappearance or new appearance of extramedullary leukemia. Relapse after PR is similarly defined with the reappearance of significant numbers of peripheral blasts and an increase in the percentage of blasts in the bone marrow aspirate to >25% not attributable to any other cause, or reappearance or new appearance of extramedullary leukemia. Subjects with increased dose level higher than the initial dose level were included in dose increases; subjects with decreased dose level lower than the initial dose level were included in the dose decreases. 
Total (N=252)
Blood creatinine Footnote: AE, adverse event; CR, complete remission; CRi, complete remission with incomplete hematologic recovery; CRp, complete remission with incomplete platelet recovery; DTH, death; HSCT, hematologic stem cell transplantation; LOE, lack of efficacy; NE, not evaluable; NR, nonresponse; OTH, other; PG, progressive disease; PR, partial remission; WD, withdrawal by subject.
The red circles (•) indicate bone marrow biopsies. The horizontal lines that do not end with a red triangle () indicating "Death" represent patients who remained alive at the end of the study. The blue triangles () represent HSCT. The protocol required bone marrow biopsies to be performed at screening and at every two cycles of gilteritinib therapy for patients who did not achieve CRc, and every three cycles for patients who achieved CRc. As shown, patients had up to 18 bone marrow biopsies performed over a 2-year period. 
